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A B S T R A C T
Objectives: (1) To assess the recurrence rate of pre-
eclampsia in women with this history before 34 weeks 
of pregnancy and thrombophilia. (2) To evaluate the
effects of low-molecular-weight heparin (LMWH) on
pregnancy outcome. 
Methods: In a multicentre retrospective study subsequent
pregnancies of women with a history of pre-eclampsia
necessitating birth before 34 weeks and thrombophilia
were analysed. Of 58 women, 26 received LMWH and
aspirin (ASA) and 32 ASA (22) or no (10) medication in
their subsequent pregnancies.
Results: In eight women treated with LMWH and 
ASA and in 16 women receiving ASA or no medication
pre-eclampsia recurred in the subsequent pregnancy. 
(OR 0.55, 95% CI 0.15-1.31) There were no significant
differences in birth weight or gestational age between
both groups. 
Conclusions: The recurrence rate of pre-eclampsia in
women with thrombophilic disorders is high in this small
retrospective study. No positive effect was found for
LMWH treatment. A multicentred randomised study has
been started to reach an adequate number of patients to
evaluate the influence of LMWH treatment. 
I N T R O D U C T I O N
Pre-eclampsia is a major problem in perinatal medicine
especially in early onset pre-eclampsia before 34 weeks
gestation. The exact cause of pre-eclampsia is unknown
and a multifactorial origin is suggested. Maladaptation of
the maternal immune system to the foetal allograft as well
as genetic factors are probably involved in its aetiology.1
More recently, several investigators confirmed the presence
of thrombophilic disorders (hereditary coagulation
abnormalities, anticardiolipin antibodies, hyperhomo-
cysteinaemia) in a substantial percentage (up to 60%) of
women with a history of severe early onset pre-eclampsia
and small-for-gestational-age (SGA) infants.2-4
The recurrence rate of pre-eclampsia in women with
this history necessitating delivery before 34 weeks and
documented thrombophilia without treatment with low-
molecular-weight heparin is still unknown. Riyazi et al.
tested a total of 276 patients with a history of pre-eclampsia
and/or foetal growth restriction for the presence of
hereditary coagulation abnormalities and anticardiolipin
antibodies. Ninety patients with pre-eclampsia and 15 patients
with isolated foetal growth restriction had haemostatic
abnormalities. In 26 patients a subsequent pregnancy
occurred and they were treated with low-molecular-weight
heparin (started directly after confirmation of a viable
intrauterine pregnancy) and low-dose aspirin (started at 10
to 12 weeks gestational age). Pre-eclampsia recurred in 38%,
and intrauterine growth restriction in 15% of pregnancies.5
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The recurrence rate in this population with known
thrombophilia is lower than two studies reporting the
recurrence rate of severe pre-eclampsia or HELLP
(haemolysis, elevated liver enzymes and low platelets)
syndrome in a population with unknown thrombophilic
status. Sibai et al.6 described a group of 125 women with a
history of severe pre-eclampsia in the second trimester
(range 18 to 27 weeks gestation), of which 108 women
had 169 subsequent pregnancies (range 1 to 4 per woman):
59 (35%) had a normotensive pregnancy and 110 (65%)
developed pre-eclampsia. Sullivan et al.7 studied 481
patients with a history of HELLP syndrome. Subsequent
gestations (n=195) occurred in 122 of 481 patients.
Available data on 161 pregnancies showed a recurrence
rate of 43%. 
There is still no treatment to reduce the recurrence of
pre-eclampsia in women with thrombophilia. Rai et al.8 did
perform a randomised study on women with pregnancies
complicated by intrauterine foetal death before 28 weeks
associated with anticardiolipin antibodies and unknown
hereditary coagulation status. Women treated with
unfractionated heparin with aspirin had better pregnancy
outcome compared with women treated with aspirin only.
However, in his study the entry criterion was recurrent foetal
death associated with anticardiolipin antibodies and primary
endpoint in this population was number of live births. 
Recently Kupferminc et al.9 published the results of an
uncontrolled study of 33 women with an earlier pregnancy
complicated by severe pre-eclampsia, abruptio placentae,
intrauterine growth retardation or intrauterine foetal
death. These women received LMWH in their subsequent
pregnancies and only 9.1% of the women developed
pregnancy complications. 
The study presented here concerned a retrospective study
of subsequent pregnancies of women with a history of
pre-eclampsia necessitating birth before 34 weeks. The
aims of this study were to evaluate the recurrence rate of
pre-eclampsia in women with thrombophilia and to test
the hypothesis if LMWH is beneficial in reducing the
recurrence of pre-eclampsia. The different treatments
consisted of low-molecular-weight heparin (LMWH) in
combination with aspirin or aspirin only or no medication.
This retrospective study was performed in advance of a
prospective randomised study to evaluate whether a study
for the effects of LMWH treatment in women with
thrombophilia would be beneficial.
M A T E R I A L S  A N D  M E T H O D S
In a retrospective study subsequent pregnancies of
women with a history of pre-eclampsia necessitating birth
before 34 weeks were analysed. Inclusion criteria were
women with an index pregnancy of pre-eclampsia leading
to birth before 34 weeks gestation and thrombophilia.
Between the period 1991 and 1998, 1146 women were
tested for thrombophilic disorders in eight Dutch hospitals
(table 1). The hereditary coagulation abnormalities included
were antithrombin deficiency, protein C deficiency, activated
protein C resistance with and without factor V Leiden
mutation, protein S deficiency and factor II mutation.
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Table 1
Results in 1146 women with a history of pre-eclampsia
necessitating delivery before 34 weeks in the period between
1991 and 1998 in eight Dutch hospitals (some women
had more than one thrombophilic disorder)
TESTED ABNORMAL
n n %
Antithrombin deficiency 1146 6 0.5
Protein C deficiency 1146 13 1
Activated protein C resistance (APCr) 1146 66 5
APCr+ factor V Leiden mutation 1146 96 8
Protein S deficiency 1146 88 8
Factor II mutation 1033 5 0.4
Anticardiolipin antibodies 990 95 9
Hyperhomocysteinaemia 990 99 10
The acquired anticardiolipin antibodies were tested as
well as hereditary/acquired hyperhomocysteinaemia. In
this period not all hospitals tested for all thrombophilic
disorders; one hospital did not test for factor II mutation
(n=113) and two hospitals did not test for anticardiolipin
antibodies and hyperhomocysteinaemia (n=156). In case
of coagulation abnormalities and anticardiolipin antibodies
five hospitals gave aspirin or no medication and three
hospitals treated with LMWH and aspirin in the subsequent
pregnancy. Hyperhomocysteinaemia was treated with
vitamin B6 and folic acid supplementation throughout
gestation in all hospitals. For each patient, the medical
records were checked to establish which treatment was
applied in the subsequent pregnancy. Outcome measure-
ment was recurrence rate of pre-eclampsia. Birth weight
and gestational age in index and subsequent pregnancy
were also compared between both groups.
Definitions of pre-eclampsia and eclampsia were used
according to the standards of the International Society
for the Study of Hypertension in Pregnancy (ISSHP).10
Pre-eclampsia was defined as pregnancy-induced hyper-
tension plus significant proteinuria after 20 weeks of
gestational age. Proteinuria was defined as excretion of
300 mg or more in 24 h or two readings of 2+ or higher on
dipstick analysis of midstream or catheter urine specimens.
HELLP syndrome was defined as the presence of (1)
haemolysis, defined by increased LDH (>600 IU/l) and
(2) elevated liver enzymes, defined as increased SGOT
(>70 IU/l) and (3) thrombocytopenia (<100 x 109/l).
Eclampsia was defined as the occurrence of generalised
convulsions during pregnancy, during labour, or within
seven days of delivery and not caused by epilepsy or other
convulsive disorders.
Laboratory tests
Normal values of each centre were tested, applying the
International Thrombophilia External Quality Assessment
within the European Concerted Action on Thrombosis
(ECAT) Foundation. The measurement procedures were
standardised for each laboratory. For details of hereditary
coagulation abnormalities see table I. All tests were per-
formed at least ten weeks post partum, and women were
not on oral contraceptives. Anticardiolipin antibodies,
immunoglobulin (Ig)G and IgM, were determined by
enzyme-linked immunosorbent assay according to the
Harris directives (all centres).11
Hyperhomocysteinaemia was diagnosed using a methionine
loading test: a blood sample for determination of the fasting
homocysteine concentration is drawn at 8 a.m. after an
overnight fast. Subsequently, an oral dose of L-methionine
(0.1g/kg body weight) is administered in orange juice. The
patients had a standardised low-methionine breakfast and
lunch. Patients were considered hyperhomocysteinaemic
when fasting normal values and/or postloading normal
values exceeded the 97.5 percentile (all centres).12
Statistical analysis
Analysis was carried out with SPSS for Windows (version
8.0, SPSS Inc., Chicago II) and Excel for Windows (version
5.0c, Microsoft Corporation). Odds ratios with 95%
confidence intervals were calculated by logistic regression
analysis. Statistical significance was defined as p<0.05.
R E S U L T S
In the total group of 1146 tested women, 407 women were
found to have 468 thrombophilic disorders i.e. hereditary
coagulation abnormalities (n=274) and/or anticardiolipin
antibodies (n=95) and/or hyperhomocysteinemia (n=99)
(table 1). In 48 women more than one thrombophilic dis-
order was found.
In this period 58 women had a subsequent pregnancy.
Twenty-six patients who had a pregnancy after the index
pregnancy received LMWH (nadroparin 2 dd 2850 IU
anti-Xa sc a day) plus aspirin (80 mg) starting between
six and 12 weeks gestational age, the other 32 patients
received aspirin (n=22) or no medication (n=10). In the
26 patients who received LMWH in combination with
aspirin, pre-eclampsia recurred in eight patients (30%).
In the 32 patients who received aspirin or no medication,
pre-eclampsia recurred in 16 patients (50%) (OR 0.55,
95% CI 0.15-1.31). The recurrence of pre-eclampsia before
34 weeks in the subsequent pregnancy was 2/26 (8%) versus
7/32 (22%) (OR 0.3, 95% CI 0.05-1.58) No difference was
found in recurrence rate in women treated with aspirin
(27%, 6/22) versus women without aspirin (40%, 4/10)
(OR 0.56, 95% CI 0.11-2.72). In subsequent pregnancies
the number of babies under the 10th percentile of birth
weight was one of 26 in women receiving LMWH and
ASA versus two of 12 in women receiving ASA alone and
one of 10 women receiving no medication. The number
of preterm deliveries before 34 weeks of gestational age
was three of 26, three of 12 and two of 10, respectively.
In table 2 the mean birth weights and mean gestational
ages of the index pregnancies and subsequent pregnancies
in the three groups are presented.
Kalk, et al. Recurrence rate of pre-eclampsia in women with thrombophilia
M A R C H  2 0 0 4 ,  V O L .  6 2 ,  N O .  3
85
Table 2
Index (i) and subsequent (s) outcome of pregnancies in women receiving low-molecular-weight heparin (LMWH) and
aspirin versus women receiving aspirin only or no medication (data presented as mean with standard deviation)
LMWH + ASA ASA NO MEDICATION
N=26 N=22 N=10 
Mean birth weight (gram) (i) 1004 (±437) 886 (±554) 1272 (±437)
Mean birth weight (gram) (s) 2956 (±583) 2497 (±954) 2697 (±1415)
Mean gestational age (days) (i) 205 (±19) 198 (±24) 204 (±26)
Mean gestational age (days) (s) 264 (±13) 257 (±23) 260 (±38)
D I S C U S S I O N
This study demonstrated that women with a history of
early onset pre-eclampsia in their index pregnancy do
have a high recurrence rate in subsequent pregnancies.
This was found for women receiving LMWH, aspirin or no
medication. As far as percentages can be reliably presented
for the small study population, the percentages found are
comparable with the study by Riyazi et al.5 She reported
from one hospital the recurrence rate of early onset pre-
eclampsia and SGA babies in women with thrombophilia
receiving LMWH and aspirin. Our study showed a low
recurrence rate of pre-eclampsia in comparison with the
studies by Sibai et al.6 and Sullivan et al.7 of women with
unknown thrombophilia. Our study did not demonstrate
significant benefit from LMWH in the recurrence rate.
The drawn conclusion should be seen within the context
of the retrospective character of the study and the limited
number of subsequent pregnancies in this population.
The insignificance can be merely a power problem.
In our study we report on subsequent pregnancies in
women checked in the hospital in which they had their
index pregnancy and thrombophilia analysis. The low
percentage of found subsequent pregnancies may in part
be responsible for this procedure. For practical reasons
we did not contact the 407 women with thrombophilic
disorders personally. From the work by Van Pampus et al.
who did consequently contact all the patients she included
in her study, we know that she found that 66% of women
with a history of HELLP syndrome had subsequent
pregnancies.13 Concerning the direction of a possible bias
it is plausible that we did not miss the severe early onset
pre-eclampsia. This is thanks to the Dutch healthcare
organisation. Preterms (<32 weeks) deliver in hospitals with
neonatal intensive care units and severe pre-eclamptic
women are advised to be treated in tertiary centres. All
Dutch hospitals with neonatal intensive care units and
tertiary centres participated in this study with the exception
of one, which was not systematically examining thrombo-
philic factors in these patients at that time.
The distribution of thrombophilic factors of this study is in
accordance with other Dutch studies.14 Various investigators
have found that the distribution of thrombophilic factors
varies per population.4,15 Factor V Leiden mutation is
common in Caucasian populations, but in African and
Asian countries the frequency is lower.14
The occurrence of pre-eclampsia in women with throm-
bophilia can be explained by excessive microthrombic
deposition within the maternal placental circulation.16
Therefore, thromboprophylaxis seems to be a logical
preventive therapy. Recently more studies have been
published of LMWH treatment in women with throm-
bophilia and recurrent foetal loss.17 However, no large
studies have been performed in women with a history of
severe pregnancy complications such as pre-eclampsia.
For years LMWH has been used as thrombophylaxis during
pregnancy.18 LMWH does not cross the placental barrier.19
In several studies the authors concluded that the use of
LMWH appears to be relatively safe and well tolerated
during pregnancy, delivery and the immediate postpartum
period.19 It has a longer half-life, better bioavailability and
less effect on platelets than unfractionated heparin.
Furthermore, it is considered to have a better thrombo-
phylactic effect and a lower risk on bleeding complications.
As the long-term use of heparin is associated with the
development of osteoporosis, bone density measurements
performed by pregnant women treated with LMWH and
untreated pregnant women showed similar bone density
loss in both groups.20 Furthermore, heparin-induced
osteoporosis is reversible when heparin is stopped.
Despite the above-mentioned items as possible therapeutic
effect and safety aspects for mother and foetus, the benefit
of LMWH treatment still has to be demonstrated. For this
reason an international multicentred trial has been started
called FRactionated heparin in women with a history of
Uteroplacental Insufficiency and Thrombophilia (FRUIT
study) in which 13 Dutch centres and two Australian centres
are participating. To enable an optimal inclusion of
patients, all gynaecologists in the Netherlands receive
information about the FRUIT study through newsletters
and from the website of the Dutch Society of Obstetrics
and Gynaecology.
C O N C L U S I O N
This study demonstrates a high recurrence rate of pre-
eclampsia in women with such a history and documented
thrombophilia and found no effect of LMWH on pregnancy
outcome. These findings support the need for an adequately
sized randomised study to evaluate the effects of treatment
with LMWH. 
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